Compare · FRLN vs RVMD
FRLN vs RVMD
Side-by-side comparison of Freeline Therapeutics Holdings plc (FRLN) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FRLN and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD carries a market cap of $37.27B.
- RVMD has hit the wire 9 times in the past 4 weeks while FRLN has been quiet.
- RVMD has more recent analyst coverage (25 ratings vs 6 for FRLN).
- Company
- Freeline Therapeutics Holdings plc
- Revolution Medicines Inc.
- Price
- -
- -
- Market cap
- -
- $37.27B
- 1M return
- -
- -8.97%
- 1Y return
- -
- +149.19%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2020
- News (4w)
- 0
- 9
- Recent ratings
- 6
- 25
Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest FRLN
- Freeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
- SEC Form 15-12G filed by Freeline Therapeutics Holdings plc
- SEC Form EFFECT filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form POS AM filed by Freeline Therapeutics Holdings plc
- SEC Form SC 13D/A filed by Freeline Therapeutics Holdings plc (Amendment)
- SEC Form SC 13E3/A filed by Freeline Therapeutics Holdings plc (Amendment)
Latest RVMD
- Director Borisy Alexis gifted 10,625 shares, decreasing direct ownership by 0.45% to 2,329,450 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 35,750 shares at a strike of $29.19 and sold $6,724,688 worth of shares (35,750 units at $188.10) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Mancini Anthony exercised 811 shares at a strike of $33.70 and sold $162,200 worth of shares (811 units at $200.00) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
- Officer Mancini Anthony sold $431,947 worth of shares (2,310 units at $186.99) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Participate in November 2026 Investor Conferences
- Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026